Trial Profile
A Phase III, multi-center, open-label study of Solithromycin in patients with respiratory tract infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Solithromycin (Primary)
- Indications Acute bronchitis; Respiratory tract infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors FUJIFILM Toyama Chemical; Toyama Chemical
- 02 Oct 2018 Status changed from active, no longer recruiting to completed.
- 21 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Nov 2016 New trial record